These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
54 related articles for article (PubMed ID: 1794681)
1. [Response to the letter by Prof. Kuhl: "Does a rise in endogenous estradiol during treatment with low-dose ovulation inhibitor signify increased risk"?]. Mall M; Werner-Zodrof I; Huber P Geburtshilfe Frauenheilkd; 1991 Dec; 51(12):1014. PubMed ID: 1794681 [TBL] [Abstract][Full Text] [Related]
2. [Hypophyseal reaction state during oral contraceptiva (author's transl)]. Gitsch E; Schneider WH; Schmid R; Spona J Wien Klin Wochenschr; 1981 Oct; 93(19):599-601. PubMed ID: 6798764 [TBL] [Abstract][Full Text] [Related]
3. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Teichmann A Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257 [TBL] [Abstract][Full Text] [Related]
5. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol. Akerlund M Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641 [TBL] [Abstract][Full Text] [Related]
6. [Oral contraception: disadvantages of estrogen reduction]. Denis C Contracept Fertil Sex (Paris); 1993 Jun; 21(6):481-8. PubMed ID: 12318238 [TBL] [Abstract][Full Text] [Related]
7. [Rationale for prescribing oral contraceptives]. Teichmann AT Wien Med Wochenschr; 1998; 148(7):171-4. PubMed ID: 9700865 [TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives in 1984. Chapler EK Iowa Med; 1984 Oct; 74(10):439-40, 442. PubMed ID: 6490338 [TBL] [Abstract][Full Text] [Related]
9. [Inhibition of ovarian function using a triphasic combination with gestodene]. Rozenbaum H Rev Fr Gynecol Obstet; 1988 Jun; 83(6):449-52. PubMed ID: 3406638 [TBL] [Abstract][Full Text] [Related]
10. [Oral contraception with low-dose progestagen]. Heinzl S Med Monatsschr Pharm; 1989 Apr; 12(4):123-4. PubMed ID: 2657358 [TBL] [Abstract][Full Text] [Related]
11. Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives. Norris LA; Bonnar J Thromb Haemost; 1994 Dec; 72(6):926-30. PubMed ID: 7740465 [TBL] [Abstract][Full Text] [Related]
12. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity. Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323 [TBL] [Abstract][Full Text] [Related]
13. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study]. Rossmanith WG; Wirth U; Gasser S; Thun B; Steffens D Zentralbl Gynakol; 1997; 119(11):538-44. PubMed ID: 9480608 [TBL] [Abstract][Full Text] [Related]
14. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive. Upton GV; Corbin A Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253 [TBL] [Abstract][Full Text] [Related]
15. Action of hormonal contraceptives on the coagulation system and some of its inhibitors. Misz M; Beck P Acta Med Hung; 1986; 43(3):301-10. PubMed ID: 2438639 [TBL] [Abstract][Full Text] [Related]
16. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
19. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781 [TBL] [Abstract][Full Text] [Related]